Macrogen, a Korean genome analysis company, said it installed NovaSeq X Plus, Illlumina’s latest production-scale sequencer, for the first time in Korea.

Illumina Korea General Manager Robert McBride (left) and Macrogen CEO Kim Chang-hoon pose in front of the NovaSeq X Plus device installed in Macrogen’s Genome Center in Geumcheon-gu, Seoul, Monday.
Illumina Korea General Manager Robert McBride (left) and Macrogen CEO Kim Chang-hoon pose in front of the NovaSeq X Plus device installed in Macrogen’s Genome Center in Geumcheon-gu, Seoul, Monday.

Macrogen plans to complete the introduction and installation of five NovaSeq X Plus devices at its Korea Genome Center, Japanese subsidiary, European subsidiary, and Psomagen, a U.S. affiliate.

NovaSeq X Plus is Illumina’s newest sequencing system that has increased the throughput of whole-genome sequencing capacity from 8,000 per year to more than 20,000 per year.

With the installation of the device, Macrogen plans to put more focus on its genome foundry business, which provides rapid and accurate consignment production and large-scale genome analysis service.

“The installation of NovaSeq X Plus makes it possible for the company to quickly introduce its cutting-edge sequencing technology to Macrogen’s customers at home and abroad,” Macrogen Vice President Lee Eung-ryoung said. “Macrogen will actively promote its genome foundry business based on its innovative capacity increase, and solidify its position as a top tier company in the genome analysis market.”

Illumina Korea General Manager Robert McBride also said, “We are very happy to introduce NovaSeq X Plus, which is applied with our most innovative sequencing technology, to Macrogen, our key global partner, for the first time in Asia.”

Through close cooperation, the two companies will do their best to provide Macrogen customers with services that fully use the features of NovaSeq X Plus, McBride added.

Copyright © KBR Unauthorized reproduction, redistribution prohibited